April class action lawsuits targeted public companies after merger terms, disclosure issues, stock declines, and prior company statements.
M&A Deals
May 11, 2026
Table of Contents
May 11, 2026
Several public companies were named in shareholder class action lawsuits or legal investigations in April 2026, drawing investor attention as law firms filed claims tied to merger terms, alleged disclosure issues, stock price declines, or prior company statements.
Class action lawsuits are often misunderstood in markets. These filings do not establish wrongdoing or liability. In many cases, they are filed after a stock has already declined or after a major corporate event, such as a takeover announcement.
The most notable companies facing class action lawsuits or shareholder investigations in April included Avanos Medical, KalVista Pharmaceuticals, TopBuild, Organon, SES AI, and Above Food Ingredients.
Class action lawsuits are rarely clean trading catalysts.
Unlike earnings reports, contract wins, FDA decisions, or buyback announcements, lawsuits usually do not create immediate new financial value. Instead, they act more as risk-management signals for investors already holding the stock.
These lawsuits can matter when they raise questions about:
The key question is whether the lawsuit introduces new risk or simply follows a stock decline or transaction that already happened.
Avanos Medical was investigated by Monteverde & Associates PC in connection with its proposed sale to affiliates of American Industrial Partners. Under the proposed transaction, Avanos shareholders would receive $25.00 per share in cash.
Avanos is a medical technology company focused on pain management and chronic care products, including non-opioid pain treatment and enteral feeding devices. Reuters reported that American Industrial Partners agreed to take Avanos private in a deal valued at about $1.27 billion, with the $25.00 per share offer representing a 72.1% premium to the prior closing price.
The stock rose 69.51% after the related event, making this the largest move in the April group. That reaction was driven by the takeover premium, not by the legal investigation itself.
Key details:
Filing / notice date: April 14, 2026
Plaintiff / law firm: Monteverde & Associates PC
Allegation: Investigation into whether Avanos’s board properly handled the proposed sale
Class period: Not provided
Related event: Proposed sale to affiliates of American Industrial Partners for $25.00 per share in cash
1-day stock move: +69.51%
Stock decline tied to original event: Not applicable
KalVista Pharmaceuticals was investigated by Monteverde & Associates PC in connection with its proposed sale to Chiesi Group. Under the proposed transaction, KalVista shareholders are expected to receive $27.00 per share in cash.
KalVista is a biopharmaceutical company focused on oral treatments for rare diseases, including hereditary angioedema. Chiesi announced it would acquire KalVista for $27.00 per share in cash, representing equity consideration of about $1.9 billion.
Shares rose 38.62% after the related event. Like Avanos, this was mainly an M&A premium reaction rather than a positive reaction to litigation.
Key details:
Filing / notice date: April 29, 2026
Plaintiff / law firm: Monteverde & Associates PC
Allegation: Investigation into whether KalVista’s board properly handled the proposed sale
Class period: Not provided
Related event: Proposed sale to Chiesi Group for $27.00 per share in cash
1-day stock move: +38.62%
Stock decline tied to original event: Not applicable
SES AI was named in a securities class action filed by Rosen Law Firm on behalf of purchasers of SES AI securities between January 29, 2025 and March 4, 2026.
SES AI develops AI-enhanced battery technologies and related systems for electric vehicles and advanced mobility applications.
The stock move listed was tied to SES AI Corporation warrants, which rose 38.28% after the event. That reaction should be treated carefully because warrant moves can be more volatile than common stock moves and may reflect liquidity, speculation, or capital structure dynamics rather than the lawsuit alone.
Key details:
Filing / notice date: April 27, 2026
Plaintiff / law firm: Rosen Law Firm
Allegation: Securities class action alleging federal securities law violations
Class period: January 29, 2025 to March 4, 2026
Related event: Securities class action filed on behalf of purchasers during the class period
1-day stock move: +38.28% for SES-WT
Stock decline tied to original event: Not provided
TopBuild was investigated by Monteverde & Associates PC in connection with its proposed sale to QXO. Under the transaction terms, TopBuild shareholders may elect to receive $505.00 in cash or 20.2 shares of QXO common stock for each TopBuild share.
TopBuild installs and distributes insulation and building products for residential and commercial construction markets. QXO announced a $17 billion deal to acquire TopBuild, with consideration structured as approximately 45% cash and 55% QXO stock, subject to proration.
Shares rose 19.48% after the related event. The move reflected the takeover offer, not the shareholder investigation itself.
Key details:
Filing / notice date: April 20, 2026
Plaintiff / law firm: Monteverde & Associates PC
Allegation: Investigation into potential shareholder claims tied to the proposed sale
Class period: Not provided
Related event: Proposed sale to QXO for $505.00 in cash or 20.2 QXO shares per TopBuild share
1-day stock move: +19.48%
Stock decline tied to original event: Not applicable
Organon was investigated by Monteverde & Associates PC in connection with its proposed sale to Sun Pharmaceutical Industries. Under the proposed transaction, Organon shareholders would receive $14.00 per share in cash.
Organon is a healthcare company focused on women’s health, biosimilars, and established medicines. Organon said Sun Pharma agreed to acquire the company for $14.00 per share in cash, valuing Organon at an enterprise value of $11.75 billion.
Shares rose 17.01% after the related event. The market reaction was tied to the acquisition premium, while the legal investigation focused on whether the sale process and terms were fair to shareholders.
Key details:
Filing / notice date: April 27, 2026
Plaintiff / law firm: Monteverde & Associates PC
Allegation: Investigation into whether Organon’s board properly handled the proposed sale
Class period: Not provided
Related event: Proposed sale to Sun Pharmaceutical Industries for $14.00 per share in cash
1-day stock move: +17.01%
Stock decline tied to original event: Not applicable
Above Food Ingredients was investigated by Portnoy Law Firm for possible securities fraud after disclosures related to its auditor resignation and delayed fiscal 2025 audit.
Above Food Ingredients is a food ingredients company focused on plant-based ingredients and supply chain operations.
Unlike the M&A-related names above, this was a more traditional securities-fraud investigation tied to prior disclosures and stock declines. The company disclosed on December 2, 2025 that its auditor had resigned in July at the company’s request. The stock fell 6.1% on that news. Then, on December 12, 2025, Above Food said the timetable for its fiscal 2025 audit had been affected and would not be completed on time, leading the company to notify Nasdaq and apply for a 180-day extension. The stock then fell 43.04% over two trading days.
Shares fell 12.49% after the April 1 legal notice, making this the clearest negative lawsuit-related reaction in the group.
Key details:
Filing / notice date: April 1, 2026
Plaintiff / law firm: Portnoy Law Firm
Allegation: Investigation into possible securities fraud tied to auditor resignation and delayed audit disclosures
Class period: Not provided
Related event: Auditor resignation disclosure and delayed fiscal 2025 audit
1-day stock move: -12.49%
Stock decline tied to original event: -6.1% on December 2, 2025, followed by -43.04% over two trading days after the December 12 audit-delay disclosure
Many securities class action lawsuits are filed after a company’s stock has already fallen sharply.
That matters because the lawsuit may not be the original catalyst. The filing often comes after another event, such as:
For investors, the original event usually matters more than the lawsuit itself.
April’s group was heavily tilted toward M&A-related shareholder investigations.
KalVista, Organon, TopBuild, and Avanos all rose sharply because the related acquisition offers created takeover premiums. The legal notices were not the reason the stocks jumped. They were investigations into whether shareholders were receiving fair value or whether boards properly handled the sale process.
That distinction matters. A stock can rise sharply on a takeover deal and still appear in class action or shareholder investigation alerts.
Class action lawsuits should usually be treated as risk alerts rather than automatic buy or sell triggers.
For existing shareholders, the key questions are:
Does the lawsuit introduce new legal or regulatory risk?
Does it affect management credibility?
Could it distract leadership from execution?
Does it change the long-term investment thesis?
Are regulators, auditors, or government agencies involved?
In most cases, the filing prompts review rather than immediate action.
Class action lawsuits can look alarming, but they are often backward-looking events tied to stock declines or corporate transactions that already occurred.
The signal becomes stronger when lawsuits cluster around the same issue, follow regulatory action, or coincide with financial restatements, executive departures, audit problems, or repeated guidance cuts.
Platforms like LevelFields track class action lawsuit announcements alongside other corporate events, helping investors identify whether legal filings are isolated noise or part of a broader pattern of risk.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE